SG11201903509QA - Methods and systems for tumor detection - Google Patents

Methods and systems for tumor detection

Info

Publication number
SG11201903509QA
SG11201903509QA SG11201903509QA SG11201903509QA SG11201903509QA SG 11201903509Q A SG11201903509Q A SG 11201903509QA SG 11201903509Q A SG11201903509Q A SG 11201903509QA SG 11201903509Q A SG11201903509Q A SG 11201903509QA SG 11201903509Q A SG11201903509Q A SG 11201903509QA
Authority
SG
Singapore
Prior art keywords
hong kong
international
shatin
subject
cancer
Prior art date
Application number
SG11201903509QA
Inventor
Eugeni Namsaraev
Yuk-Ming Dennis Lo
Rossa Wai Kwun Chui
Kwan Chee Chan
Peiyong Jiang
Kun Sun
Wai Kei Lam
Original Assignee
Univ Hong Kong Chinese
Grail Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Hong Kong Chinese, Grail Inc filed Critical Univ Hong Kong Chinese
Publication of SG11201903509QA publication Critical patent/SG11201903509QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/708—Specific hybridization probes for papilloma
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/10—Ploidy or copy number detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/05—Epstein-Barr virus
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Primary Health Care (AREA)

Abstract

d cfDNA Extraction 2210 (54) Title: METHODS AND SYSTEMS FOR TUMOR DETECTION FIG. 22 2207 Negative Target Assess EBV Enrichment Sequenci quantity and Library Prep (or EBV ng on size profile Target Enrichment] NextSeq of EBV DNA fragments 2214 2213 2211 2212 2201 2202 Yes 2204 2205 qPCR setup • 4m1 plasma for NGS workflow Blood Plasma Samples y Separation collected in 2X spin + 2 tubes automation 2203 Plasma for qPCR workflow cfDNA Extraction (51) International Patent Classification: C12Q 1/68 (2018.01) GOOF 19/18 (2011.01) GO1N 33/574 (2006.01) (21) International Application Number: PCT/US2017/058099 (22) International Filing Date: 24 October 2017 (24.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/411,929 24 October 2016 (24.10.2016) US 62/450,541 25 January 2017 (25.01.2017) US 62/507,154 16 May 2017 (16.05.2017) US (71) Applicants: THE CHINESE UNIVERSITY OF HONG KONG [CN/CN]; Room 301, Pi Ch'iu Building, Shatin, New Territories, Hong Kong (CN). GRAIL, INC. [US/US]; 1525 O'Brien Drive, Menlo Park, California 94025 (US). (72) Inventors: NAMSARAEV, Eugeni; 3772 La Donna Av- enue, Palo Alto, California 94306 (US). LO, Yuk-Ming Dennis; 4th Floor, 7 King Tak Street, Homantin, Kowloon, Hong Kong (CN). CHUI, Rossa Wai Kwun; House 31, Double Haven, 52 Ma Lok Path, Shatin, New Territories, Hong Kong (CN). CHAN, Kwan Chee; Flat C, 15th Floor, Block 5, Peak One, Mei Tin Road, Shatin, New Territo- ries, Hong Kong (CN). JIANG, Peiyong; Flat 7, 1/F, Block B, Kwong Lam Court, 62-66 Siu Lek Yuen Road, Shatin, New Territories, Hong Kong (CN). SUN, Kun; Rm 711, Block A, Staff Quarters, Prince of Wales Hospital, 30-32 Ngan Sling ST., Shatin, New Territories, Hong Kong (CN). 1-1 O co O co O C (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 03 May 2018 (03.05.2018) WIP0 I PCT Hu omit VIII °nolo III m 01110111110 111110 oimIE (10) International Publication Number WO 2018/081130 Al ( Report ) 2215 (57) : Methods are provided to improve the positive predictive value for cancer detection using cell-free nucleic acid samples. Various embodiments are directed to applications (e.g., diagnostic applications) of the analysis of the fragmentation patterns and size of cell-free DNA, e.g., plasma DNA and serum DNA, including nucleic acids from pathogens, including viruses. Embodiments of one application can determine if a subject has a particular condition. For example, a method of present disclosure can determine if a subject has cancer or a tumor, or other pathology. Embodiments of another application can be used to assess the stage of a condition, or the progression of a condition over time. For example, a method of the present disclosure may be used to determine a stage of cancer in a subject, or the progression of cancer in a subject over time (e.g., using samples obtained from a subject at different times). [Continued on next page] WO 2018/081130 Al MIDEDIMOMOIDEIREEMOOMMH10100110MEHOIS LAM, Wai Kei; Flat B, 3/F, Block 14, Beacon Heights, 14 Lung Ping Road, Kowloon, Hong Kong (CN). (74) Agent: HARIHARAN, Venkatesh et al.; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
SG11201903509QA 2016-10-24 2017-10-24 Methods and systems for tumor detection SG11201903509QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662411929P 2016-10-24 2016-10-24
US201762450541P 2017-01-25 2017-01-25
US201762507154P 2017-05-16 2017-05-16
PCT/US2017/058099 WO2018081130A1 (en) 2016-10-24 2017-10-24 Methods and systems for tumor detection

Publications (1)

Publication Number Publication Date
SG11201903509QA true SG11201903509QA (en) 2019-05-30

Family

ID=62025423

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903509QA SG11201903509QA (en) 2016-10-24 2017-10-24 Methods and systems for tumor detection

Country Status (9)

Country Link
US (2) US11459616B2 (en)
EP (1) EP3535415A4 (en)
CN (1) CN110100013A (en)
AU (1) AU2017347790B2 (en)
CA (1) CA3041647A1 (en)
MY (1) MY195527A (en)
SG (1) SG11201903509QA (en)
TW (2) TW202340477A (en)
WO (1) WO2018081130A1 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110016499B (en) 2011-04-15 2023-11-14 约翰·霍普金斯大学 Safety sequencing system
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
CN104956225B (en) 2012-10-29 2018-10-02 约翰·霍普金斯大学 Ovary and the test of the Pap test of carcinoma of endometrium
US20150197790A1 (en) * 2014-01-10 2015-07-16 Bio-Rad Laboratories, Inc. Intercalating dyes for differential detection
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
US11286531B2 (en) 2015-08-11 2022-03-29 The Johns Hopkins University Assaying ovarian cyst fluid
KR102326769B1 (en) 2016-03-25 2021-11-17 카리우스, 인코포레이티드 Synthetic nucleic acid spike-ins
MY195527A (en) 2016-10-24 2023-01-30 Grail Inc Methods And Systems For Tumor Detection
EP3574108A4 (en) 2017-01-25 2020-12-23 The Chinese University Of Hong Kong Diagnostic applications using nucleic acid fragments
US11319602B2 (en) * 2017-02-07 2022-05-03 Tcm Biotech Internationl Corp. Probe combination for detection of cancer
KR20200035427A (en) * 2017-07-26 2020-04-03 더 차이니즈 유니버시티 오브 홍콩 Augmentation of cancer screening using cell-free viral nucleic acids
MX2020001575A (en) 2017-08-07 2020-11-18 Univ Johns Hopkins Methods and materials for assessing and treating cancer.
TW202012639A (en) * 2018-04-24 2020-04-01 美商格瑞爾公司 Systems and methods for using pathogen nucleic acid load to determine whether a subject has a cancer condition
KR20210039406A (en) * 2018-07-23 2021-04-09 더 차이니즈 유니버시티 오브 홍콩 Cell-free DNA damage analysis and clinical application thereof
US10721069B2 (en) 2018-08-18 2020-07-21 Eygs Llp Methods and systems for enhancing privacy and efficiency on distributed ledger-based networks
WO2020060994A1 (en) * 2018-09-17 2020-03-26 The University Of North Carolina At Chapel Hill Method for quantifying dna fragments in a sample by size
WO2020076772A1 (en) * 2018-10-08 2020-04-16 Freenome Holdings, Inc. Transcription factor profiling
US11572586B2 (en) * 2018-10-12 2023-02-07 Life Technologies Corporation Methods and systems for evaluating microsatellite instability status
EP3884087A4 (en) * 2018-11-21 2022-09-07 Karius Inc. Detection and prediction of infectious disease
JP2022514879A (en) * 2018-12-19 2022-02-16 ザ チャイニーズ ユニバーシティ オブ ホンコン Cell-free DNA terminal characteristics
EP3696279A1 (en) * 2019-02-13 2020-08-19 Nipd Genetics Public Company Limited Methods for noninvasive prenatal testing of fetal abnormalities
EP3696278A1 (en) * 2019-02-13 2020-08-19 Nipd Genetics Public Company Limited Method of determining the origin of nucleic acids in a mixed sample
WO2020206041A1 (en) * 2019-04-02 2020-10-08 Grail, Inc. Stratification of risk of virus associated cancers
US11316691B2 (en) 2019-04-15 2022-04-26 Eygs Llp Methods and systems for enhancing network privacy of multiple party documents on distributed ledger-based networks
US11206138B2 (en) * 2019-05-02 2021-12-21 Ernst & Young U.S. Llp Biosignature-based tokenization of assets in a blockchain
WO2020232109A1 (en) * 2019-05-13 2020-11-19 Grail, Inc. Model-based featurization and classification
EP3973080A4 (en) 2019-05-22 2023-05-31 Grail, LLC Systems and methods for determining whether a subject has a cancer condition using transfer learning
WO2021016441A1 (en) 2019-07-23 2021-01-28 Grail, Inc. Systems and methods for determining tumor fraction
US11232439B2 (en) 2019-08-09 2022-01-25 Eygs Llp Methods and systems for preventing transaction tracing on distributed ledger-based networks
US11481841B2 (en) 2019-11-20 2022-10-25 Eygs Llp Systems, apparatus and methods for identifying distinguishing characteristics of fungible assets using zero-knowledge proof on a distributed ledger-based network
AU2021205853A1 (en) * 2020-01-08 2023-11-23 Grail, Inc. Biterminal dna fragment types in cell-free samples and uses thereof
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
CA3169488A1 (en) 2020-02-28 2021-09-02 Collin MELTON Identifying methylation patterns that discriminate or indicate a cancer condition
AU2021227920A1 (en) 2020-02-28 2022-09-08 Grail, Llc Systems and methods for calling variants using methylation sequencing data
CN115702457A (en) 2020-03-04 2023-02-14 格里尔公司 System and method for determining cancer status using an automated encoder
KR20220154141A (en) 2020-03-16 2022-11-21 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Compositions and methods for selective detection of tumor-derived viral DNA
US20210302425A1 (en) * 2020-03-26 2021-09-30 Deborah Ann Payne Methods for detecting the presence of bacteria, fungi, parasites, and viruses in a test sample and treating a patient
CA3180231A1 (en) 2020-04-15 2021-10-21 Eygs Llp Intelligent assertion tokens for authenticating and controlling network communications using a distributed ledger
WO2021258026A1 (en) * 2020-06-19 2021-12-23 Tempus Labs, Inc. Molecular response and progression detection from circulating cell free dna
WO2021257854A1 (en) * 2020-06-20 2021-12-23 Grail, Inc. Detection and classification of human papillomavirus associated cancers
AU2021305654A1 (en) * 2020-07-10 2023-03-02 Progenics Pharmaceuticals, Inc Methods of making prostate cancer treatment decisions
CN111898694B (en) * 2020-08-07 2021-09-17 广东电网有限责任公司计量中心 Non-invasive load identification method and device based on random tree classification
WO2022054086A1 (en) * 2020-09-08 2022-03-17 Indx Technology (India) Private Limited A system and a method for identifying genomic abnormalities associated with cancer and implications thereof
CN112149036B (en) * 2020-09-28 2023-11-10 微梦创科网络科技（中国）有限公司 Method and system for identifying batch abnormal interaction behaviors
IL302784A (en) * 2020-12-08 2023-07-01 Univ Hong Kong Chinese Methods using characteristics of urinary and other dna
CN113160889B (en) * 2021-01-28 2022-07-19 人科(北京)生物技术有限公司 Cancer noninvasive early screening method based on cfDNA omics characteristics
CA3227495A1 (en) 2021-08-05 2023-02-09 Grail, Inc. Somatic variant cooccurrence with abnormally methylated fragments
CN114023442B (en) * 2021-11-12 2023-07-14 上海市第一人民医院 Student information analysis method and model based on bone and meat tumor molecular typing of multiple groups of chemical data
US11788152B2 (en) 2022-01-28 2023-10-17 Flagship Pioneering Innovations Vi, Llc Multiple-tiered screening and second analysis
US20230313314A1 (en) * 2022-02-07 2023-10-05 Centre For Novostics Limited Fragmentation for measuring methylation and disease
AU2023220947A1 (en) * 2022-02-16 2024-01-18 Illumina, Inc. Minimizing fetal fraction bias in maternal polygenic risk score estimation
WO2023170298A1 (en) * 2022-03-11 2023-09-14 Belgian Volition Srl Differential diagnosis method

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219765A1 (en) 2000-03-23 2003-11-27 Jose Costa Methods for evaluating cancer risk
EP1342794B1 (en) 2002-03-05 2005-12-14 Epigenomics AG Method and device for determination of tissue specificity of free floating DNA in bodily fluids
WO2004078999A1 (en) 2003-03-05 2004-09-16 Genetic Technologies Limited Identification of fetal dna and fetal cell markers in maternal plasma or serum
ATE435301T1 (en) 2003-10-16 2009-07-15 Sequenom Inc NON-INVASIVE DETECTION OF FETAL GENETIC CHARACTERISTICS
WO2005108621A1 (en) 2004-04-30 2005-11-17 Yale University Methods and compositions for cancer diagnosis
CN1790021A (en) 2004-12-15 2006-06-21 杨华显 Screening of preinvasive carcinoma, carcinoma in situ and carcinoma focus by using DNA of circulating epstein-barr virus
US20070122823A1 (en) 2005-09-01 2007-05-31 Bianchi Diana W Amniotic fluid cell-free fetal DNA fragment size pattern for prenatal diagnosis
ES2739483T3 (en) 2006-02-02 2020-01-31 Univ Leland Stanford Junior Non-invasive fetal genetic detection by digital analysis
WO2007100911A2 (en) 2006-02-28 2007-09-07 University Of Louisville Research Foundation Detecting fetal chromosomal abnormalities using tandem single nucleotide polymorphisms
US7842482B2 (en) 2007-02-26 2010-11-30 The Chinese University Of Hong Kong Methods and kits for diagnosis, prognosis or monitoring of Epstein-Barr virus (EBV)-associated cancer
US20100112590A1 (en) 2007-07-23 2010-05-06 The Chinese University Of Hong Kong Diagnosing Fetal Chromosomal Aneuploidy Using Genomic Sequencing With Enrichment
PL2557520T3 (en) 2007-07-23 2021-10-11 The Chinese University Of Hong Kong Determining a nucleic acid sequence imbalance
US20090053719A1 (en) 2007-08-03 2009-02-26 The Chinese University Of Hong Kong Analysis of nucleic acids by digital pcr
WO2010112316A1 (en) 2009-03-31 2010-10-07 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Method for diagnosis of cancer and monitoring of cancer treatments
EP2483426A4 (en) 2009-10-02 2013-04-10 Ct For Addiction And Mental Health Method for analysis of dna methylation profiles of cell-free circulating dna in bodily fluids
WO2011053790A2 (en) 2009-10-30 2011-05-05 Fluidigm Corporation Assay of closely linked targets in fetal diagnosis and coincidence detection assay for genetic analysis
HUE061110T2 (en) 2009-11-05 2023-05-28 Univ Hong Kong Chinese Fetal genomic analysis from a maternal biological sample
JP5770737B2 (en) 2009-11-06 2015-08-26 ザ チャイニーズ ユニバーシティ オブ ホンコン Genome analysis based on size
EP2558854B1 (en) 2010-04-16 2018-10-10 Chronix Biomedical Breast cancer associated circulating nucleic acid biomarkers
EP2426217A1 (en) 2010-09-03 2012-03-07 Centre National de la Recherche Scientifique (CNRS) Analytical methods for cell free nucleic acids and applications
CA2817370C (en) 2010-11-30 2022-02-01 The Chinese University Of Hong Kong Detection of genetic or molecular aberrations associated with cancer
US20120190021A1 (en) 2011-01-25 2012-07-26 Aria Diagnostics, Inc. Detection of genetic abnormalities
US20140178348A1 (en) 2011-05-25 2014-06-26 The Regents Of The University Of California Methods using DNA methylation for identifying a cell or a mixture of cells for prognosis and diagnosis of diseases, and for cell remediation therapies
EP2761001B1 (en) 2011-09-26 2018-08-01 Qiagen GmbH Rapid method for isolating extracellular nucleic acids
PL2768985T3 (en) 2011-10-21 2019-10-31 Chronix Biomedical Colorectal cancer associated circulating nucleic acid biomarkers
EP2771483A1 (en) 2011-10-25 2014-09-03 ONCOTYROL - Center for Personalized Cancer Medicine GmbH Method for diagnosing a disease based on plasma-dna distribution
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
US11261494B2 (en) 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
WO2014004726A1 (en) 2012-06-26 2014-01-03 Caifu Chen Methods, compositions and kits for the diagnosis, prognosis and monitoring of cancer
US10988803B2 (en) 2014-12-29 2021-04-27 Life Genetics Lab, Llc Multiplexed assay for quantitating and assessing integrity of cell-free DNA in biological fluids for cancer diagnosis, prognosis and surveillance
EP4036247B1 (en) 2012-09-04 2024-04-10 Guardant Health, Inc. Methods to detect rare mutations and copy number variation
NZ717423A (en) 2012-09-20 2017-08-25 Univ Hong Kong Chinese Non-invasive determination of methylome of fetus or tumor from plasma
US9732390B2 (en) 2012-09-20 2017-08-15 The Chinese University Of Hong Kong Non-invasive determination of methylome of fetus or tumor from plasma
US20150119260A1 (en) 2013-10-18 2015-04-30 National Taiwan University Circulating cancer biomarker and its use
LT4026917T (en) 2014-04-14 2024-03-12 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. A method and kit for determining the death of cells or tissue or the tissue or cell origin of dna by dna methylation analysis
RU2016147914A (en) 2014-05-09 2018-06-18 Лайфкодекс Аг DETECTION OF DNA THAT COMES FROM A SPECIFIC CELL TYPE AND RELATED TO IT
US9840742B2 (en) 2014-06-16 2017-12-12 JBS Science Inc. Detection of hepatitis B virus (HBV) DNA and methylated HBV DNA in urine of patients with HBV-associated hepatocellular carcinoma
US20160002717A1 (en) 2014-07-02 2016-01-07 Boreal Genomics, Inc. Determining mutation burden in circulating cell-free nucleic acid and associated risk of disease
TWI758011B (en) 2014-07-18 2022-03-11 香港中文大學 Methylation pattern analysis of tissues in a dna mixture
US20170211143A1 (en) 2014-07-25 2017-07-27 University Of Washington Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
US10570443B2 (en) 2014-10-01 2020-02-25 Chronix Biomedical Methods of quantifying cell-free DNA
EP3227464B1 (en) 2014-12-05 2022-04-20 Foundation Medicine, Inc. Multigene analysis of tumor samples
EP3567120B1 (en) * 2014-12-12 2020-08-19 Verinata Health, Inc. Using cell-free dna fragment size to determine copy number variations
US11242559B2 (en) 2015-01-13 2022-02-08 The Chinese University Of Hong Kong Method of nuclear DNA and mitochondrial DNA analysis
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
US10319463B2 (en) 2015-01-23 2019-06-11 The Chinese University Of Hong Kong Combined size- and count-based analysis of maternal plasma for detection of fetal subchromosomal aberrations
WO2016127944A1 (en) * 2015-02-10 2016-08-18 The Chinese University Of Hong Kong Detecting mutations for cancer screening and fetal analysis
US20160273049A1 (en) 2015-03-16 2016-09-22 Personal Genome Diagnostics, Inc. Systems and methods for analyzing nucleic acid
WO2017012592A1 (en) 2015-07-23 2017-01-26 The Chinese University Of Hong Kong Analysis of fragmentation patterns of cell-free dna
US10428391B2 (en) 2015-07-27 2019-10-01 The Johns Hopkins University Method to use viral and host methylation markers for cervical cancer screening and triage in liquid prep, serum/plasma, and urine: PCR and sequencing based process methods
SG11201805115PA (en) 2015-12-18 2018-07-30 Lucence Diagnostics Pte Ltd Detection and quantification of target nucleic acid sequence of a microorganism
MY195527A (en) 2016-10-24 2023-01-30 Grail Inc Methods And Systems For Tumor Detection
EP3574108A4 (en) * 2017-01-25 2020-12-23 The Chinese University Of Hong Kong Diagnostic applications using nucleic acid fragments
KR20200035427A (en) 2017-07-26 2020-04-03 더 차이니즈 유니버시티 오브 홍콩 Augmentation of cancer screening using cell-free viral nucleic acids

Also Published As

Publication number Publication date
TWI797095B (en) 2023-04-01
US11459616B2 (en) 2022-10-04
TW201833329A (en) 2018-09-16
AU2017347790B2 (en) 2024-06-13
WO2018081130A1 (en) 2018-05-03
US20230132951A1 (en) 2023-05-04
CN110100013A (en) 2019-08-06
EP3535415A4 (en) 2020-07-01
AU2017347790A1 (en) 2019-05-23
US20180237863A1 (en) 2018-08-23
CA3041647A1 (en) 2018-05-03
MY195527A (en) 2023-01-30
EP3535415A1 (en) 2019-09-11
TW202340477A (en) 2023-10-16

Similar Documents

Publication Publication Date Title
SG11201903509QA (en) Methods and systems for tumor detection
SG11201906397UA (en) Diagnostic applications using nucleic acid fragments
Harrell et al. Statistical comparison of Afirma GSC and Afirma GEC outcomes in a community endocrine surgical practice: early findings
SG11201908396PA (en) Methods of treating tumor
SG11201903158RA (en) Methods for cell label classification
SG11201908564RA (en) Devices, processes, and systems for determination of nucleic acid sequence, expression, copy number, or methylation changes using combined nuclease, ligase, polymerase, and sequencing reactions
SG11201805217XA (en) Compositions and methods for the treatment of hemoglobinopathies
SG11201805906WA (en) Diagnostic and prognostic methods for cardiovascular diseases and events
SG11201902925PA (en) Phenotype/disease specific gene ranking using curated, gene library and network based data structures
SG11201805451TA (en) Immune effector cell therapies with enhanced efficacy
SG11201906938WA (en) Method for non-invasive monitoring of fluorescent tracer agent with diffuse reflection corrections
SG11201809913PA (en) Methods for detecting target nucleic acids in a sample
SG11201908509TA (en) Biosensors for biological or chemical analysis and methods of manufacturing the same
SG11201806190TA (en) Isotachophoresis for purification of nucleic acids
SG11201903519UA (en) Methods and systems for barcoding nucleic acid molecules from individual cells or cell populations
SG11201907663XA (en) Method and device for constructing scoring model and evaluating user credit
SG11201805119QA (en) Methods to determine tumor gene copy number by analysis of cell-free dna
SG11201810924WA (en) System and method for secondary analysis of nucleotide sequencing data
SG11201901783UA (en) A device to manipulate ions of same or different polarities
SG11201806100PA (en) Apparatus of plural charged-particle beams
SG11201810611YA (en) Coumarin compounds and their uses as fluorescent labels
SG11201810544WA (en) Detecting hematological disorders using cell-free dna in blood
SG11201900509YA (en) Simultaneous capturing of overlay signals from multiple targets
SG11201806609TA (en) Cancer evolution detection and diagnostic
SG11201811408PA (en) Adoptive cell transfer and oncolytic virus combination therapy